Defining outcomes for beta cell replacement therapy: a work in progress

Lorenzo Piemonti; Eelco J P de Koning; Thierry Berney; Jon S Odorico; James F Markmann; Peter G Stock; Michael R Rickels

doi:10.1007/s00125-018-4588-0

Defining outcomes for beta cell replacement therapy: a work in progress

Lorenzo Piemonti, Eelco J P de Koning, Thierry Berney, Jon S Odorico, James F Markmann, Peter G Stock, Michael R Rickels

Hubrecht Institute

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

11 Citations (Scopus)

Abstract

Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.

Original language	English
Pages (from-to)	1273-1276
Number of pages	4
Journal	Diabetologia
Volume	61
Issue number	6
DOIs	https://doi.org/10.1007/s00125-018-4588-0
Publication status	Published - Jun 2018

Keywords

Blood Glucose/analysis
C-Peptide/analysis
Europe
Glycated Hemoglobin A/analysis
Guidelines as Topic
Humans
Hypoglycemia/diagnosis
International Cooperation
Islets of Langerhans Transplantation/methods
Pancreas Transplantation/methods
Patient Satisfaction
Societies, Medical
Treatment Outcome

Access to Document

10.1007/s00125-018-4588-0

Cite this

@article{75257204215d42f1bd2b0ac90724664b,

title = "Defining outcomes for beta cell replacement therapy: a work in progress",

abstract = "Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.",

keywords = "Blood Glucose/analysis, C-Peptide/analysis, Europe, Glycated Hemoglobin A/analysis, Guidelines as Topic, Humans, Hypoglycemia/diagnosis, International Cooperation, Islets of Langerhans Transplantation/methods, Pancreas Transplantation/methods, Patient Satisfaction, Societies, Medical, Treatment Outcome",

author = "Lorenzo Piemonti and {de Koning}, {Eelco J P} and Thierry Berney and Odorico, {Jon S} and Markmann, {James F} and Stock, {Peter G} and Rickels, {Michael R}",

year = "2018",

month = jun,

doi = "10.1007/s00125-018-4588-0",

language = "English",

volume = "61",

pages = "1273--1276",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Verlag GmbH",

number = "6",

}

TY - JOUR

T1 - Defining outcomes for beta cell replacement therapy

T2 - a work in progress

AU - Piemonti, Lorenzo

AU - de Koning, Eelco J P

AU - Berney, Thierry

AU - Odorico, Jon S

AU - Markmann, James F

AU - Stock, Peter G

AU - Rickels, Michael R

PY - 2018/6

Y1 - 2018/6

N2 - Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.

AB - Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.

KW - Blood Glucose/analysis

KW - C-Peptide/analysis

KW - Europe

KW - Glycated Hemoglobin A/analysis

KW - Guidelines as Topic

KW - Humans

KW - Hypoglycemia/diagnosis

KW - International Cooperation

KW - Islets of Langerhans Transplantation/methods

KW - Pancreas Transplantation/methods

KW - Patient Satisfaction

KW - Societies, Medical

KW - Treatment Outcome

U2 - 10.1007/s00125-018-4588-0

DO - 10.1007/s00125-018-4588-0

M3 - Article

C2 - 29511779

SN - 0012-186X

VL - 61

SP - 1273

EP - 1276

JO - Diabetologia

JF - Diabetologia

IS - 6

ER -

Defining outcomes for beta cell replacement therapy: a work in progress

Abstract

Keywords

Access to Document

Fingerprint

Cite this